Ubiquitin-conjugating enzyme E2T regulates cell proliferation and migration in cholangiocarcinoma
- 1 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 31 (8) , 836-846
Abstract
Ubiquitin-conjugating enzyme E2T (UBE2T) is overexpressed in several human cancer cells, but a role in cholangiocarcinoma (CAA) progression has not been investigated. We analyzed the expression of UBE2T in CAA tissues. Then, we generated UBE2T deregulation models in which it was overexpressed or silenced, and examined the effects on CAA malignant progression by flow cytometry, western blot, MTT assay, wound healing assay and transwell assay. We report the involvement of UBE2T in CAA malignant progression. UBE2T was found to be highly expressed in human CAA cells both in vitro and in vivo. Overexpression of UBE2T significantly enhanced epithelial-to-mesenchymal transition, proliferation, migration and invasion of CAA cells in vitro, while silencing UBE2T had opposing effects. Furthermore, UBE2T appears to exert its effects via the mammalian target of rapamycin (mTOR) pathway as the cellular effects caused by UBE2T overexpression are inhibited by the mTOR inhibitor rapamycin. Our findings suggest that UBE2T may have potential as a new therapeutic target for the prevention or treatment of CAA.Keywords
This publication has 30 references indexed in Scilit:
- mTORC1 and mTORC2 Regulate EMT, Motility, and Metastasis of Colorectal Cancer via RhoA and Rac1 Signaling PathwaysCancer Research, 2011
- Ubiquitination and Downregulation of BRCA1 by Ubiquitin-Conjugating Enzyme E2T Overexpression in Human Breast Cancer CellsCancer Research, 2009
- UBE2T Is the E2 in the Fanconi Anemia Pathway and Undergoes Negative AutoregulationMolecular Cell, 2006
- Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on the Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United StatesJNCI: Journal of the National Cancer Institute, 2006
- CholangiocarcinomaCurrent Treatment Options in Gastroenterology, 2005
- CholangiocarcinomaThe Lancet, 2005
- Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression ProfilingClinical Cancer Research, 2005
- Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate CancerCancer Research, 2004
- A Review and Update on CholangiocarcinomaOncology, 2004
- Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugsOncogene, 2003